Nitin Pal Kalia

Employment

• National Institute of Pharmaceutical Education and Research Assistant Professor
  2021 - Present
• Nanyang Technological University Research Fellow
  2015 - 2019
• National Institute of Allergy and Infectious Diseases Visiting Fellow
  2014 - 2015
• Indian Institute of Integrative Medicine CSIR Senior Research Fellow
  2014 - 2014
• CSIR-IIIM Ramalingaswami Fellow
  2009 - 2021
• Indian Institute of Integrative Medicine CSIR Project Assistant Level II
  2007 - 2009

Education

• Indian Institute of Integrative Medicine CSIR Ph.D
  2009 - 2014
• Guru Nanak Dev University Masters
  2004 - 2006
• Himachal Pradesh University Bachelors (B.Sc)
  2001 - 2004

Projects & Funding

Projects & funding information is unavailable.

Publications (47)

• Delineating the potential of bioenergetics in drug discovery against Mycobacterium abscessus
  Tuberculosis 2026 DOI: 10.1016/j.tube.2026.102784
  +Save
• Exploiting NDH-2 Vulnerability: Quinolines as Antitubercular Agents
  2026 DOI: 10.64898/2026.06.08.730781
  +Save
• Simultaneous Inhibition of Cytochrome bd Oxidase and ATP Synthase for Complete Eradication of Mycobacterium tuberculosis
  ACS Infectious Diseases 2026 DOI: 10.1021/acsinfecdis.5c01066
  +Save
• Development and evaluation of fenticonazole nitrate-loaded, fucoidan-coated lecithin–chitosan nanoparticles for the treatment of vaginitis
  RSC Pharmaceutics 2026 DOI: 10.1039/D5PM00345H
  +Save
• Exploiting NDH-2 Vulnerability: Quinolines as Antitubercular Agents
  2026 DOI: 10.2139/ssrn.6872766
  +Save
• Exploration of Novel Indolo[2,3-b]quinoxaline Hybrids as InhA Inhibitors: A Multi-disciplinary Approach Involving In Silico Screening, Synthesis, and Antimycobacterial Evaluation
  2026 DOI: 10.2139/ssrn.6913221
  +Save
• Mechanistic Insights into MmpL3 Inhibition of Mycobacterium tuberculosis by FDA Approved Ethacridine
  2026 DOI: 10.2139/ssrn.6306528
  +Save
• Mechanistic Insights into MmpL3 Inhibition of Mycobacterium tuberculosis by FDA approved Ethacridine
  2026 DOI: 10.2139/ssrn.6506749
  +Save
• Quinoline-Mediated NDH-2 Inhibition Disrupts Redox Homeostasis and Bioenergetics in Mycobacterium tuberculosis
  2026 DOI: 10.2139/ssrn.7206782
  +Save
• Synthesis and biological evaluation of quinoline-8-amides as cytochrome bd oxidase inhibitors to combat respiratory flexibility in Mycobacterium tuberculosis
  Journal of Molecular Structure 2026 DOI: 10.1016/j.molstruc.2026.146801
  +Save